Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results
February 27, 2024 06:00 ET
|
Privia Health Group, Inc.
Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results; Achieved All 2023 Operating and Financial Guidance Metrics
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023 10:00 ET
|
Tiziana Life Sciences Ltd.
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
October 11, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...
Professional Diversity Network, Inc. Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021
March 31, 2022 15:00 ET
|
Professional Diversity Network, Inc.
CHICAGO, March 31, 2022 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN), (“IPDN” or the “Company”), a global developer and operator of online and in-person networks that...
Scanfil revises upwards its turnover and adjusted operating profit outlook for 2021
June 11, 2021 01:00 ET
|
Scanfil Oyj
Scanfil plc Stock exchange release 11 June 2021 8.00 amScanfil revises upwards its turnover and adjusted operating profit outlook for 2021Due to strong customer demand, Scanfil revises upwards...
Scanfil Oyj nostaa tulosohjeistustaan vuoden 2021 liikevaihdon ja oikaistun liikevoiton osalta
June 11, 2021 01:00 ET
|
Scanfil Oyj
Scanfil Oyj Pörssitiedote 11.6.2021 klo 8.00Scanfil Oyj nostaa tulosohjeistustaan vuoden 2021 liikevaihdon ja oikaistun liikevoiton osaltaVahvan asiakaskysynnän johdosta Scanfil nostaa vuoden...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 01, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel,...
A Very Hairy Hare Teaches Kids to Accept Their Unique Qualities and Respond to Everyone With Positivity in New Children’s Book
August 17, 2020 10:00 ET
|
Archway Publishing
HOUGHTON, Mich., Aug. 17, 2020 (GLOBE NEWSWIRE) -- As a lifetime anti-bullying advocate, retired educator Dan Wohlleber releases his debut children’s book with a message about how kids can be a...
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
October 07, 2019 06:30 ET
|
Capricor Therapeutics, Inc.
--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET-- ...
Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 06, 2019 16:00 ET
|
Capricor Therapeutics, Inc.
Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...